News (Updated
December 11, 2011)
[Home]
[Previous
news]
(AFP) – 8 December 2011
People age 12 and over who
test positive for TB or have been exposed but show no symptoms are among those
who could benefit from the shorter treatment, the US Centers for Disease Control
and Prevention said.
A total of 8.8 million
people around the world fell ill with the contagious lung disease last year and
1.4 million died, according to the World Health Organization.
Three randomized
controlled trials have shown that a new combination regimen that includes
isoniazid (INH) and rifapentine (RPT), given weekly under a doctor's
supervision, "is as effective for preventing TB as other regimens,"
the CDC said.
The shorter treatment
"is more likely to be completed than the
Tuberculosis develops in
five to 10 percent of people who get infected by Mycobacterium tuberculosis,
usually after a period of six to 18 months when the infection lies dormant, but
it can endure decades in some people.
Isoniazid (INH) is the
only medication approved by the US Food and Drug Administration for preventive
therapy against latent TB.
"However,
self-supervised daily INH regimens have completion rates of 60% or less in
typical settings, attributable largely to the duration of six or more
months," the CDC said.
In cases in which the TB
is believed to be a drug-resistant strain, patients are often given daily
rifampin (
The new, shorter treatment
combines a similar antibiotic to
The CDC recommended the
shorter combination treatment for people over 12 who have been recently exposed
to TB, have tested positive for infection or show evidence of healed pulmonary
TB after a radiological scan.
"HIV-infected
patients who are otherwise healthy and are not taking antiretroviral medications
also are included in this category," it added.
In order to choose which
approach is best, patients and doctors should consider whether there is adequate
access to a physician for weekly treatments, how easy or hard it is to get the
drugs, and personal preference, the CDC said.
Copyright © 2011 AFP.